Overselling hysteria, dangerously: the media coverage of testosterone therapy in men by Vance, Jay
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2015
Overselling hysteria, dangerously:
the media coverage of testosterone
therapy in men
https://hdl.handle.net/2144/16342
Boston University
   
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
OVERSELLING HYSTERIA, DANGEROUSLY: THE MEDIA COVERAGE OF  
 
TESTOSTERONE THERAPY IN MEN 
 
 
 
 
by 
 
 
 
 
JAY C. VANCE 
 
B.S., The Ohio State University, 2012 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2015  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 by 
 JAY C. VANCE 
 All rights reserved  
   
Approved by 
 
 
 
 
First Reader   
 Abdulmaged Traish, Ph.D. 
 Professor of Biochemistry  
 Professor of Urology 
 
 
Second Reader  
 Carl Franzblau, Ph.D. 
 Professor of Biochemistry 
 
 
 
 
  iv
OVERSELLING HYSTERIA, DANGEROUSLY: MEDIA COVERAGE OF 
TESTOSTERONE THERAPY IN MEN 
JAY C. VANCE 
ABSTRACT 
 Testosterone has been used therapeutically for over 70 years in men 
suffering from the symptoms of testosterone deficiency (TD, hypogonadism), and 
a strong body of evidence suggests testosterone treatment is safe and 
efficacious in patients for whom it is indicated.  Additionally, there exists sufficient 
data to recognize male hypogonadism as a risk factor for cardiovascular disease.  
Four recently published studies suggested that testosterone therapy is 
associated with myocardial infarction, stroke, and death.  Although these studies 
are afflicted with poor study design, flawed data analysis and misinterpretations, 
and received nearly unanimous rejection by experts in the field, the mainstream 
media has catapulted the studies into the public spotlight with sensationalist 
headlines, creating a hysteria that has had far-reaching and dangerous 
implications for patients and physicians.  The media-driven hysteria has created 
an environment in which pharmaceutical companies are being sued, physicians 
are withholding treatment from men suffering from testosterone deficiency, and 
the United States Food and Drug Administration has been petitioned to place a 
black box warning on testosterone products.  The imbalanced media coverage 
has crossed a grave ethical line by interfering in the patient-physician relationship 
to the extent that patients are being harmed.  
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 1 
INTRODUCTION 
 
 The humble beginnings of testosterone research date back to 1849, when 
Arnold Berthold, a German zookeeper, experimented with rooster castration and 
testicular re-implantation1.  He determined that some substance secreted by the 
testis into the blood gave roosters their biologically male characteristics.  From 
that point on, other animal studies and forms of human self-experimentation 
began to appear sporadically in the medical literature in an attempt to identify 
and utilize this substance.  In 1920, physiologist Eugene Steinach devised a 
surgical procedure to treat the symptoms that what would later be recognized as 
those of testosterone deficiency2.  The “Steinach operation” comprised a 
unilateral vasectomy, which Steinach posited would shift the functional balance 
of the testes away from spermatogenesis and toward increased hormone 
production.  Although the benefits of the procedure were never substantiated, 
Steinach’s work represents one of the earliest interventions designed to treat 
hypogonadism. 
The tale of what is perhaps the most significant breakthrough in the field of 
male sex hormones occurred shortly thereafter and was recently reviewed in 
spectacular detail by Freeman et al2.  To summarize, Adolf Butendant, a German 
chemist, isolated a male sex hormone from the urine of policemen in 19313.  He 
identified this hormone as andosterone, and a Swiss chemist named Leopold 
Ruzicka devised a method to synthesize it in 19342.  After a Dutch group 
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published a paper identifying testosterone in early 19354, Butendant and Ruzicka 
simultaneously published papers describing methods for preparing synthetic 
testosterone.  The two researchers were offered the Nobel prize for chemistry in 
1939 for their groundbreaking work2. 
In 1940, Dr. Joseph Aub published a report on medical progress in the 
New England Journal of Medicine reviewing all data available at the time relating 
to the therapeutic use of testosterone.  He concluded, “From this report of the 
practical use of testosterone in clinical medicine it is obvious that the drug is a 
potent one, particularly in hypogonadism in males. In this condition its 
effectiveness as substitution therapy is uniformly accepted.”5  Then, in 1943, Aub 
and his colleague Dr. Seymour Kety published another paper detailing the 
advances in testosterone therapy during the intervening three years6.  The 
evidence presented in this article strengthened the argument for testosterone 
substitution therapy in male hypogonadism, and suggested that the hormone 
may have beneficial effects in many other diseases. 
Also in 1943, Dr. Maurice Lesser experimented with the testosterone 
propionate ester as a treatment for angina pectoris7, or chest pain caused by 
coronary heart disease.  He treated 46 patients, 41 men and 5 women, who 
suffered from the syndrome with a single 25 mL injection every 2-5 days for an 
average of 11 injections, and compared the results to those of a control group 
receiving injections of plain sesame oil.  Lesser reported in the New England 
Journal of Medicine, “The frequency, severity and duration of attacks were 
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diminished, and all patients were able to increase their physical activity 
considerably without precipitating an attack of pain.”7.  In many patients, he also 
observed lower blood pressure.  Interestingly, these favorable effects persisted 
for 2-12 months after the testosterone treatment was stopped. 
Based largely on the work of Aub and Lesser, the United States Food and 
Drug Administration approved testosterone therapy for the treatment of 
hypogonadism in men in the 1950s8.  For the better part of the past century, 
testosterone therapy has continued to offer a host of benefits to millions of men 
suffering from testosterone deficiency.   
Recently, however, testosterone therapy and its proponents have moved 
into the crosshairs of the mainstream media.  Fueled by four studies linking 
testosterone therapy to cardiovascular disease that have been unanimously 
rejected by the scientific community, newspapers and television outlets have 
created a culture of hysteria and fear surrounding this legitimate medical 
treatment that has been studied for over 150 years.  This unethical coverage has 
had widely applicable consequences, including unwarranted lawsuits against the 
pharmaceutical industry and physicians withholding treatment from their patients.  
This review aims to objectively evaluate the methodology and conclusions of 
these four studies, compile and summarize other literature relevant to the topic, 
examine the themes consistently present in the media’s coverage, discuss the 
far-reaching implications of the hysteria, and determine why testosterone therapy 
is an easy and interesting target that journalists know will drive readership.    
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ESSENTIAL PHYSIOLOGY 
Testosterone Deficiency and Testosterone Therapy in Hypogonadal Men 
 
 Simply put, hypogonadism is symptomatic testosterone deficiency.  More 
specifically, the Endocrine Society9 recommends “making a diagnosis of 
androgen deficiency only in men with consistent symptoms and signs and 
unequivocally low serum testosterone levels.”  The authoritative organization  
places the lower limit of the normal range for total testosterone at ~300ng/dL, and 
enumerates the symptoms and signs as shown in table 19.  According to the 
European Association of Urology guidelines on male hypogonadism10, there are 
three classifications of the syndrome: 
• Primary hypogonadism is caused by a testicular abnormality that results 
in failure to produce adequate levels of testosterone.   
• Secondary hypogonadism reflects a defect in the pituitary gland or 
hypothalamus, affecting levels of tropic hormone (GnRH) and/or 
gonadotropin (LH and FSH).   
• Combined hypogonadism involves defects affecting both the gonads and 
endocrine glands. 
To distinguish between the three, clinicians are advised to measure serum 
LH and FSH.  In primary hypogonadism, there is very little testosterone available 
to regulate secretion the pituitary gonadotrophs via the negative feedback loop, 
so FSH and LH levels will be elevated.  Conversely, in secondary hypogonadism, 
defects in the hypothalamus and pituitary cause decreased levels of FSH and 
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LH.  In combined hypogonadism, the serum LH and FSH levels will vary 
according to which cause is more prevalent.   
Table 1. Symptoms and signs suggestive of 
testosterone deficiency in men.[Taken from the 
Endocrine Society Clinical Practice Guideline 
Testosterone Therapy in Adult Men with Androgen 
Deficiency Syndromes9]. 
 
 
 
 
 
 
 
Klinefelter’s syndrome, vericoceles, chemotherapy, orchitis, environmental 
toxins, and various other rare genetic conditions can underlie primary 
hypogonadism.  Radiation exposure, trauma, pituitary adenomas, certain 
medications, sleep apnea, diabetes mellitus, chronic kidney disease, infection, 
hypothyroidism, Kallman syndrome, and Prader-Willi syndrome may contribute to 
secondary hypogonadism11.   
A strong body of evidence, established as early as 195812–21 supports the 
idea that the incidence of androgen deficiency increases as men age.  Serum 
testosterone levels have been reported to decrease by 0.4-2.0% per year21–24.  
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Importantly, the Baltimore Longitudinal Study on Aging (BLSA)24, a longitudinal 
study of 890 men with a mean age of 58.8 ± 15.8, found 19% of men over the 
age of 60, 28% of men over 70, and 49% of men over age 81 had total serum 
testosterone levels below the reference range.  Additionally, the BLSA showed 
that sex hormone binding globulin (SHBG), a protein that binds and inactivates 
androgens in the blood, increases at a rate of 1.2% per year. Free, or 
bioavailable, testosterone also decreases with age (see figure 1).  
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Figure 1. Effects of age (left panels) and date (right panels) on serum T, SHBG, and free T 
index [Taken from Harman et al.24]. Top row: Total testosterone levels tended to decrease as 
the men aged.  The curvilinear regression in the top left panel suggests total testosterone drops 
at faster rate in elderly men than in younger men.  Middle row: SHBG concentrations correlate 
positively in a curvilinear manner with age.  The observed rate of increase was greater in older 
men than in younger men.  Bottom row:  Like total testosterone, free testosterone levels 
decreased with age in a curvilinear pattern, decreasing at a greater rate in older men than in 
younger men.    
 
As reviewed by Kaufman and Vermeulen22, there are three primary 
mechanisms by which this condition, referred to as late-onset hypogonadism or 
andropause, occurs: 
First, the male gonads undergo primary changes such that the number of 
Leydig cells decreases, reducing the testicular secretory capacity25.  This finding 
is consistent with the lower testicular volume observed in older men26.  
Furthermore, animal studies suggest that enzymes involved in steroidogenesis 
diminish with age27.  
Second, aging correlates with an alteration in the hypothalamic control of 
Leydig cell function.  As men age, serum LH levels increase modestly20, likely 
due to decreased metabolic clearance28.  However, it is not the mean serum 
levels, but the pulsatile LH secretion that governs Leydig cell function.  These 
pulses, elicited by GnRH, diminish in magnitude in the elderly29.  Thus, it may be 
that the alteration in neuroendocrine control of the Leydig cells is seen at the 
level of the hypothalamus.   
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Third, as mentioned in the BLSA24, SHBG levels increase as men age, 
resulting in lower levels of free testosterone.  Normally men compensate for an 
increase in SHBG and maintain free testosterone levels by increasing gonadal 
testosterone production, but, as discussed, there is diminished Leydig cell 
secretory capacity in the elderly. 
Testosterone Therapy and Cardiovascular Disease 
  It is well established that testosterone plays an important role in erectile 
function, libido, energy, bone density, and maintenance of lean body mass.  
Interestingly, there is data to suggest that testosterone may protect against 
cardiovascular disease and all-cause mortality, and untreated testosterone 
deficiency should absolutely be recognized as a risk factor for cardiovascular 
disease.  As discussed, testosterone was used successfully as early as 1943 to 
treat angina pectoris7. 
In 2006, Shores et al. published a novel study correlating low testosterone 
levels to increased mortality in a population of 858 male veterans30.  In a 2010 
prospective study of 930 men with coronary artery disease, Malkin et al. 
confirmed this finding by reporting that four parameters impacted the time to all-
cause mortality: left ventricular dysfunction, aspirin therapy, β-blocker therapy, 
and low serum bioactive testosterone.  In their discussion, the authors state, “low 
endogenous bio-T is related to all-cause and vascular mortality in a coronary 
disease population. TT is weakly associated with survival and a cut-off of TT of 
less than 15.1 nmol/l is related to increased mortality. Therefore, we also 
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conclude that borderline low levels of TT may also adversely impact on 
survival.”31  These two studies are supported by several others32–38 in their 
findings.  Additionally, in a study of 308 men with sexual dysfunction, Lee et al. 
reported a significant negative correlation between total testosterone levels and 
cardiovascular risk as, stating in their conclusion, “high testosterone level may 
decrease the risk of cardiovascular disease.”  Yeap et al.39 corroborated these 
findings in a study of 3,690 men over the age of 70, reporting that a higher 
plasma testosterone level is a biomarker for reduced risk of stroke. 
As reviewed by Traish40, testosterone deficiency may pose numerous 
other cardiovascular related dangers to those who suffer from it, including 
dyslipidemia19, endothelial dysfunction41, and hypertension42.   
Clearly, the overwhelming majority of the available data suggests 
testosterone levels negatively correlate to adverse cardiovascular events: 
hypogonadal men are at a higher risk for cardiovascular disease than eugonadal 
men.  Unsurprisingly, there is also evidence that testosterone therapy in 
hypogonadal men may reduce the incidence of cardiovascular disease.  
Recently, Baillargeon et al. examined a large cohort from a database of Medicare 
beneficiaries and found “Older men who were treated with intramuscular 
testosterone did not appear to have an increased risk of MI. For men with high MI 
risk, testosterone use was modestly protective against MI.”43  In a large 
observational study of 934,283 men, Etminan et al.44 found no association 
between past or current testosterone therapy and myocardial infarction.  
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Similarly, Tan et al. found “no evidence of worsening preexisting MI or stroke in 
patients treated with testosterone.” in a cohort of 39,936 men45.   
Within the past five years, four studies have been published46–49  
correlating testosterone therapy in men to cardiovascular risk: a prematurely-
terminated clinical trial, a meta-analysis, and two retrospective observational 
studies.  It will be made clear in this review that these studies are fraught with 
methodological and experimental design problems, data mismanagement, as 
well as a myriad of statistical complexities with more variables and 
extrapolations, which makes analysis and interpretation of such data very 
difficult; notwithstanding, the mainstream media has selfishly and irresponsibly 
rendered in the public eye the idea that these four studies represent irrefutable 
truth and that the pharmaceutical industry has medicalized a normal aspect of 
aging for the sake of profit.  The perpetuation of these myths on the front pages 
of national and regional newspapers and on various social media outlets has had 
several unfortunate consequences, including physicians halting treatment of a 
legitimate medical condition, unwarranted class action lawsuits against 
healthcare providers and drug manufacturers, a call for the FDA to place a black 
box warning on testosterone products, and a witch hunt directed against 
proponents of testosterone therapy.  
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STUDIES CLAIMING A LINK BETWEEN TESTOSTERONE AND 
CARDIOVASCULAR DISEASE 
On February 25, 2014, the consumer advocacy organization Public Citizen 
officially petitioned50 the Food and Drug Administration (FDA) to “add a black box 
warning about the increased risks of heart attacks and other cardiovascular 
dangers to the product labels of all testosterone containing drugs presently on 
the market in the U.S… [and] to ask manufacturers to send “Dear Doctor” letters 
to warn physicians of these serious adverse effects”.  This petition was 
subsequently denied by the FDA51, but an examination of the evidence it 
contains is useful to gain an appreciation for what little evidence exists linking 
testosterone to cardiovascular problems. 
To support their argument, the petitioners cited four noteworthy studies46–
49.  Despite contradicting a strong body of evidence spanning a decade 
suggesting testosterone therapy is safe and may have cardiovascular 
benefits30,32,3352,35,34,53,54,38,55,56,37,57,31,58,59,36,60–63, these four studies have received 
a disproportionate amount of favorable media coverage.  In the following 
sections, we will examine the four studies and the coverage they have received, 
discuss the implications for patients and physicians, and explore why 
testosterone therapy has become such a hot-button issue in the mainstream 
media.   
Basaria et al., Adverse Events Associated with Testosterone 
Administration. (NEJM 2010)46 
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The first paper indicating a significant increase in cardiovascular risk 
associated with testosterone therapy was published in 2010 by Basaria et al. in 
the New England Journal of Medicine.  The study, referred to as the 
Testosterone in Older Men with Mobility Limitations (TOM) trial, was designed to 
evaluate the effects of testosterone therapy in hypogonadal men over the age of 
65 with evidence of limitations in mobility.  The cohort comprised 209 men who 
had a total serum testosterone level between 100 and 350 ng/dL or a free serum 
testosterone level of less than 50 pg/mL.  A portion of the men were randomly 
assigned to daily application of a testosterone gel (n=106), and the remaining 
men were assigned a placebo gel (n=103).  However, the trial was aborted just 
four years after enrollment began because a data and safety monitoring board 
determined a significantly higher incidence of cardiovascular-related events in 
the group receiving testosterone gel as compared to the placebo group. 
Although the premature results of the Basaria study are ostensibly 
troubling, the authors’ study design, analysis, and conclusions have been 
categorically refuted by the FDA and expert academicians in the field of 
testosterone therapy.  Indeed, for the reasons explained below, the title of this 
publication is misleading, inappropriate, and inaccurate. 
In response to the Public Citizen black-box petition, the FDA wrote, “the 
Basaria study… had several significant limitations that precluded a definitive 
assessment in the role of testosterone therapy in cardiovascular events noted in 
the study”51.  Indeed, Basaria et al. admitted, “the lack of a consistent pattern in 
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these events and the small number of overall events suggest the possibility that 
the differences detected between the two trial groups may have been due to 
chance alone.”46  When the FDA examined only major adverse cardiac events 
(MI, stroke, and death due to MI or stroke), they found only an insignificantly 
small imbalance in the incident of events between the testosterone and placebo 
groups51.  Furthermore, the randomized groups were not balanced for preexisting 
cardiovascular risk factors. 
In their discussion of a potential mechanism for testosterone to increase 
cardiovascular risk, Basaria et al. mention that “the use of anabolic steroids has 
been associated with left ventricular hypertrophy.”  The two studies64,65 cited to 
substantiate this assertion are wholly irrelevant to the matter of testosterone 
treatment in hypogonadal men.  From the title of the both references, it is clear 
the publications addresses only the chronic misuse of anabolic steroids.  The 
second cited65 study found that effect is potentiated by concomitant use of growth 
hormone, further distancing its results from those of the Basaria study.   
The Endocrine Society Clinic Practice Guidelines9 recommends a regimen 
of 5-10g of 1% testosterone gel containing 50-100mg applied daily.  The 
testosterone group in the TOM trial was started on the maximum recommended 
dose, 10g of transdermal gel containing 100mg of testosterone applied once per 
day, and the dose for some participants was increased to 15g during the course 
of the study.  The authors caution against “extrapolating these findings to other 
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doses and formulations”46, which would include all submaximal doses 
recommended by the Endocrine Society.   
Importantly, as described in the trial design and methods publication from 
March 200966, the primary objective of this study was “determine whether 
testosterone therapy in older men with low testosterone levels and mobility 
limitations will increase maximal voluntary muscle strength as measured by the 1 
repetition maximum.”  In fact, assessing cardiovascular outcomes was 
completely omitted from the initial trial design publication.  Thus, there existed a 
severe limitation regarding the ascertainment of the cardiovascular events.     
Xu et al., Testosterone therapy and cardiovascular events among men: a 
systematic review and meta-analysis of placebo-controlled randomized 
trials. (BMC 2013)47 
The Public Citizens petition also adduces an April 2013 meta-analysis of 
27 placebo-controlled randomized trials of testosterone therapy in men that 
reported cardiovascular events.  The meta-analysis evaluated 2,994 men, 1,733 
of whom received testosterone therapy and 1,261 of whom received placebo, 
treated for 12 weeks between 1986 and 2012.  Overall, Xu et al. reported a 54% 
higher incidence rate of cardiovascular-related events in the testosterone groups 
as compared to the placebo groups.  Specifically, in studies not funded by the 
pharmaceutical industry, they found a two-fold increase in the incidence of 
cardiovascular events in the testosterone group. 
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The FDA pointed out several methodological issues in the design and 
execution of the 27 component studies, such as inappropriately broad definitions 
of cardiovascular-related events that included hypotension, bleeding esophageal 
varices, syncope, and peripheral edema51.  They also suggested the discrepancy 
in outcomes based on funding source may have been due to chance. 
In a commentary on the Xu study, Morgentaler et al.67 determined that 2 of 
the 27 trials included in the meta-analysis accounted for a disproportionate 35% 
of the reported cardiovascular related-events.  The first of these two studies was 
conducted in 1986 and examined the effects of supraphysiological doses of an 
oral testosterone formulation in men with alcoholic cirrhosis68.  Ironically, the 
Endocrine Society recommends against the use of orally-active testosterone due 
to hepatotoxicity of the compounds9.  For this reason, it is inaccurate to 
extrapolate the 16 cardiovascular events reported in the 1986 study testosterone 
group to the treatment of hypogonadal men with approved testosterone 
formulations.  The second study46, published by Basaria et al. in NEJM and 
addressed earlier in this section, is rife with severe limitations.   
The primary data from this meta-analysis demonstrate that there were 6.6 
reported cardiovascular-related events per 100 men in the testosterone group, as 
compared to 5.2 in the placebo group.  The modesty of this asymmetry alone is 
enough to reject Xu et al.’s conclusion that testosterone therapy increases 
cardiovascular-related events among men.  Moreover, if the two outlier trials 
mentioned previously46,68 are removed from the primary data, the incidence of 
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cardiovascular events in the testosterone group falls to 4.9 events per 100 men 
in the group treated with testosterone, versus 5.1 events per 100 men in the 
placebo group. 
Vigen et al., Association of Testosterone Therapy With Mortality, 
Myocardial Infarction, and Stroke in Men With Low Testosterone Levels. 
(JAMA 2013)48 
In early November 2013, a group from the University of Texas and 
University of Colorado led by Rebecca Vigen published a study in the Journal of 
the American Medical Association (JAMA) titled Association of Testosterone 
Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low 
Testosterone Levels.  The study aimed to identify whether an association 
between testosterone therapy and mortality, myocardial infarction, and stroke 
existed in a retrospective cohort of hypogonadal men who underwent coronary 
angiography from 2005 to 2011 in the Veterans Affairs system.  Ostensibly, the 
authors reported a significantly higher 25.7% risk of cardiovascular events in the 
group receiving testosterone therapy three years after the coronary angiography, 
as compared to 19.9% in the control group.  Delving deeper into the study’s 
statistical analysis, it is clear that the raw data was grossly misrepresented. 
First, the statistical analysis was accomplished using stabilized inverse 
propensity treatment weighting (IPTW) applied to a Kaplan-Meier estimator with 
testosterone therapy as a time-varying covariate.  In a paper published in 
January 2012 by Michael P. Ho69, senior author of the Vigen et. Al study, he 
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admitted the methodology is “challenging and needs further study.”67.  Just two 
months after the JAMA was published, an official correction70 was issued, 
altering the wording to demonstrate the complexity of the statistical methodology. 
Second, the authors adjusted for 57 variables, but failed to adjust for 
serum testosterone measured at baseline71.  In a study by Lee et al.72, higher 
serum testosterone levels were associated with a lower Framingham Risk Score, 
a predictor of 10-year cardiovascular outcome risks (see figure 2).  In the Vigen 
et al. study, the group that did not receive testosterone therapy had a mean 
baseline total testosterone level of 206.5ng/dL, versus 175.5ng/dL in the group 
receiving testosterone.  Extrapolating the findings from Lee et al. to the Vigen et 
al. study, it would be expected that the no treatment group would have better 
cardiovascular outcomes regardless of treatment.  
 
 
Figure 2.  Representation of correlation analysis between testosterone levels and FRS 
[Taken from Lee et al72].  Panel (A) depicts a negative correlation between adverse 
cardiovascular outcomes as represented by the Framingham Risk Score (FRS) and the total 
 18 
testosterone level. Panel (B) suggests a negative correlation between the FRS and the free 
testosterone levels. 
 
Third, in an invited commentary published in The Journal of Sexual 
Medicine in response to the JAMA article, Traish et al.71 reexamined the raw data 
from the study, stripping away the layers of complex statistical masking, and 
found that there was actually a lower rate of cardiovascular events in the group 
receiving testosterone therapy (see Figure 3).  Additionally, Shores et. al30 
reported strikingly similar results in a separate observational study, examining 
1031 hypogonadal male patients in the Veterans Affairs database.  They found a 
20.7% mortality in the no-treatment group after 3-5 year, as compared to just 
10.3% in the group receiving testosterone therapy. These findings are consistent 
with a growing body of strong evidence suggesting testosterone therapy has 
cardioprotective effects67.  
 
Figure 3. Actual association between cardiovascular events and testosterone therapy in 
the Vigen et al. study48 [Taken from Traish et al71]. The left graph shows the absolute rate of 
death, myocardial infarction (MI), and stroke in untreated men (black) and men receiving 
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testosterone therapy (white) based on the primary data of Vigen et al.  The right graph depicts the 
absolute total event rate of death, myocardial infarction (MI), and stroke in untreated (black) and 
men receiving testosterone therapy (white), also from the Vigen et al. primary data. 
 
Fourth, Traish et al.71 discovered that Vigen et al. excluded 1,132 subjects 
who received testosterone therapy after experiencing an adverse cardiovascular 
event.  The events these men suffered clearly should have been included in the 
no treatment group.  Just one day after the publication of Traish et al.’s 
commentary revealing this egregious oversight, JAMA issued a second official 
correction70, including 1,004 of the aforementioned men who had previously been 
excluded.  Somewhat comically, it was also disclosed that Vigen et al. had 
mistakenly included 100 women in the study.   
The Androgen Study Group (ASG) is a consortium of clinicians and 
scientists that formed largely in response to the Vigen et al. article.  Their 
mission, as stated on their website, is “to ensure that the results of research 
regarding testosterone deficiency and its treatment are presented accurately and 
fairly within medical literature and to the public.”  To date, 29 medical societies 
and greater than 160 medical professionals 67 from around the world have signed 
the ASG petition calling for an official retraction of the Vigen et al. study from 
JAMA.  
Finkle et al., Increased Risk of Non-Fatal Myocardial Infarction Following 
Testosterone Therapy Prescription in Men. (PLoS One 2014)49 
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In January 2014, a third study purporting an association between 
testosterone therapy and increased cardiovascular risk was published by Finkle 
et al. in PLoS One.  In a secondary data analysis of a large healthcare database, 
55,593 were identified as having filled a prescription for testosterone.  The 
incidence rate of myocardial infarction (MI) in the 90 days following the first 
testosterone prescription was compared to the MI incidence rate for the year 
prior to the initial prescription.  These same intervals were also compared for 
167, 279 men who were prescribed a phosphodiesterase 5 inhibitor (PDE5I), a 
drug primarily used to treat erectile dysfunction, who served as a control group.  
Overall, the study reported a 36% increase in the incidence rate of MI in for men 
who had filled a testosterone prescription, as compared to an 8% increase in 
men prescribed a PDE5I.  Additionally, in men over the age of 65 prescribed 
testosterone, the MI incidence rate increased by 119%, versus 15% in the PDE5I 
group.  However, this study was severely limited in several aspects. 
As this study was merely an examination of diagnoses codes and 
prescription information, there is no verifiable data available regarding the 
patients’ adherence to the testosterone therapy.  There exist three subgroups 
within the testosterone group based on the endpoints to which they were 
followed: (1) men who refilled their prescription at least once in the first 90 days 
and did not experience an MI before the refill, (2) men who went the entire 90 
days with neither an MI nor a prescription refill, and (3) men who experienced an 
MI before refilling their prescription.  Although this study does not provide this 
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information, it is likely that the patients in group 1 were adherent to their 
prescription and refilled at the typical 30 day point.  Conversely, group 2 likely did 
not adhere to the prescribed treatment as evidenced by their lack of refill.  As the 
study does not provide data regarding how many of the 65 post-prescription MI 
cases occurred in day 1-30 versus day 31-90, it is unclear whether the patients in 
group 3 who experienced an MI were adherent to treatment.  It is well known that 
the administration of exogenous testosterone suppresses the gonadal production 
of endogenous testosterone.  Moreover, there is evidence that low serum 
testosterone is associated with an increased risk of cardiovascular events72.  
Therefore, it is entirely plausible that many of the patients who experienced an MI 
were noncompliant with their treatment.  Theoretically, if the men in group 3 used 
testosterone briefly and then abruptly discontinued treatment, their serum 
testosterone would drop to very low levels, increasing their risk for MI.   
Moreover, the researchers did not have access to any clinical data.  They 
were unable to adjust for BMI, social history, blood pressure, and blood test 
values indicative of cardiovascular risk, including baseline serum testosterone or 
cholesterol.   
Lastly, as elaborated by Dupree et al.73 in a published response to the 
PLoS One study, it was inappropriate to use the patients receiving PDE5I 
prescriptions as a control group.  Sildenafil, more commonly known as Viagra, 
was discovered in an attempt to treat angina, and is currently indicated in the 
treatment of pulmonary hypertension.  Both of these conditions have severe 
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cardiovascular implications.  Preclinical studies suggest PDE5i may protect 
against MI, ischemia/reprofusion injury, cardiotoxicity of certain medications, and 
heart failure74,75.  Additionally, a recent meta-analysis found that PDE5I may 
have cardioprotective properties in patients with left ventricular hypertrophy 
(LVH)76.  Finkle et al. chose PDE5I as a comparison because the drugs “have not 
been associated with adverse cardiovascular events.”49  While true, the authors 
failed to mention the possible cardiovascular benefits of PDE5I, which may have 
artificially lowered the number of cardiovascular events observed in the 
comparison group. 
Despite the embarrassingly poor study design, irresponsible data 
management, distorted statistical analysis, and unanimous repudiation by 
authorities in various relevant fields, theses three articles received an 
overwhelming amount of media attention.  
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EVALUATION OF MEDIA COVERAGE 
 
Quick Study: Testosterone supplement may have cardiovascular risks for 
older men (Washington Post, 2010)77 
“This study involved 209 men, who averaged 74 years old and had low 
testosterone levels and mobility problems…They were randomly assigned to 
apply a testosterone gel (Testim) or a placebo gel daily. After six months, those 
using testosterone recorded greater improvements in lower-extremity strength 
and physical functioning. However, twice as many men in the testosterone group 
were evaluated for a medical problem. This included 23 men who had a 
cardiovascular problem (including high blood pressure, arrhythmia, stroke and a 
need for stenting), compared with five men in the placebo group, and seven (vs. 
one) who had an atherosclerosis-related problem (including heart attack, 
angioplasty and coronary artery bypass).”   
This Washington Post article, reporting the results from the TOM trial by 
Basaria et al.46, marks the first time an academic study linking testosterone 
therapy to cardiovascular risks appeared in one of the top ten most circulated 
newspapers in the United States.  Aside from not recognizing several of the 
problems with the Basaria study noted in the previous section, this article was 
relatively objective and pointed out that the authors conceded "the differences 
detected between the two trial groups may have been due to chance alone."46.  
This manner of balanced discussion would soon all but vanish in the following 
articles as testosterone therapy became a popular target for journalists.    
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Testosterone Treatments Linked to Heart Risk (USA Today, 2013)78 
“Testosterone treatments may increase risks for heart attacks, strokes and 
death in older men with low hormone levels and other health problems, a big 
Veterans Affairs study suggests… Men who used testosterone were 30 percent 
more likely to have a heart attack or stroke or to die during a three-year period 
than men with low hormone levels who didn't take the supplements.” 
This Associated Press piece published in the USA Today reports on the 
Vigen study48 discussed earlier.  As shown, the highly statistical approach and 
poor data management to this study has resulted in its unanimous rejection by 
experts in the field.   
Overselling Testosterone Dangerously (New York Times, 2014)79  
“A large study has found substantial risks in prescribing testosterone to 
middle-age and older men for a variety of ailments. One part of the study found 
that testosterone doubled the risk of cardiovascular disease in more than 7,000 
men who were 65 years old or older, essentially confirming findings in previous 
studies. The other part found that testosterone almost tripled the risk of heart 
attacks in a group of more than 48,000 middle-age men with previous histories of 
heart disease. The harm in both cases occurred within 90 days of receiving the 
prescription… Drug companies have shamelessly pushed the notion, to doctors 
and to the public, that their testosterone-boosting product can overcome a 
supposed disease called “low T,” which is characterized by feelings of fatigue, 
loss of sexual drive, depressed moods, an increase in body fat and decrease in 
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muscle strength, among other symptoms... Men need to recognize the dangers 
of seeking a quick fix for aging, and doctors need to be more cautious in 
prescribing.” 
The scornfully succinct editorial begins by summarizing the reported 
results from the Finkle et al. study49 addressed earlier, touting it as “the most 
compelling evidence yet that many American men have embarked on a perilous 
course of overtreatment.”  As we have shown, the Finkle study was gravely 
limited, which is why the FDA rejected it as insufficient evidence for a black-box 
warning, stating, “it is difficult to attribute the increased risk for non-fatal MI seen 
in the Finkle study to testosterone alone”51.   
The NYT piece also reported that “in a striking comparison, it found that 
drugs used to treat erectile dysfunction, such as Viagra and Cialis, which are 
often prescribed for similar purposes, did not increase heart risks.”  As previously 
explained, this finding is the antithesis of ‘striking.’  Based on a wealth of 
evidence available to the authors, this mundane finding would be expected by 
any scientifically literate individual who read the methods section of the study.  
However, as none of the 19 members of the NYT Editorial Board has a formal 
education in science, it may indeed have been shocking to them.  
Lastly, there is no doubt that aging is associated with decreasing 
testosterone levels22, but that certainly does not mean it should be shrugged off 
as part of the aging process and not treated.  Macular degeneration is associated 
with aging, yet it is treated with anti-angiogenic drugs and laser therapy80; 
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hypertension is associated with aging, yet it is treated with a vast array of 
drugs81; type 2 diabetes is associated with aging, yet it is treated with hormone 
therapy and other drugs82; hearing loss is associated with aging, yet it is treated 
with hearing aids and cochlear implants83; hyperlipidemia is associated with 
aging, yet it is treated with some of the most frequently prescribed drugs on the 
market84; osteoporosis is associated with aging, yet it is treated vitamin and 
mineral supplementation and several medications85; rheumatoid arthritis is 
associated with aging, yet it is treated with steroids, biologics, and surgery86; 
gastroesophageal reflux disease is associated with aging, yet it is treated with H-
2-receptor blockers and proton pump inhibitors87; urinary incontinence is 
associated with aging, yet it is treated with anticholinergic drugs and surgery88.  
Just because a medical condition is associated with age, it does not follow that it 
should not be treated.  Unfortunately, some licensed physicians in the United 
States have opened “anti-aging clinics,” relying on testosterone, human growth 
hormone, and thyroid hormone therapy to make their clients feel younger.  At this 
time, there is insufficient evidence to use testosterone therapy as “a quick fix for 
aging” in and of itself.  Such clinics represent irresponsibly practiced medicine 
and reflect poorly on board-certified endocrinologists, urologists, and primary 
care physicians who administer testosterone therapy responsibly to hypogonadal 
men.   
Don’t Ask Your Doctor About ‘Low T’ (New York Times, 2014)89  
 27 
Just one day before Overselling Testosterone, Dangerously hit the pages 
of the New York Times, the newspaper published an Op-Ed from internist Dr. 
John La Puma, also highlighting the Finkle Study49.  He proceeded to make 
several claims regarding testosterone therapy that are not supported by scientific 
evidence: 
“In addition to the cardiac risks, prescription T can mean a permanent 
shut-off in men’s own, albeit diminished, testosterone production.”89 This 
assertion is simply not true.  To our knowledge, there has never been a 
documented case of testosterone therapy irreversibly inhibiting the HPG axis.  
Additionally, hypogonadism is not a disease that spontaneously corrects itself; 
testosterone is intended as a lifelong treatment, and any physician who has read 
best practice guidelines will discuss this with patients before initiating therapy.  
“Instead of heading to the pharmacy to get their fix, men should address 
the leading cause of the problem. Losing weight is a tried and true way to 
naturally boost testosterone levels.”89 With the heterogeneity in clinical 
presentation of hypogonadism, it is absurd to attribute the majority of cases to 
high body fat.  While it may be true that the majority of hypogonadal men are 
overweight90, evidence has shown that testosterone therapy in these men 
produces sustained weight loss91.  Therefore, in this chicken-and-the-egg 
scenario, it is likely that low serum testosterone contributes to obesity more 
significantly than obesity contributes to low serum testosterone.   
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“The last thing they need now is a prescription for a risky drug to treat a 
trumped-up disease.”  Amusingly, Dr. La Puma is the author of a book titled 
“Refuel: A 24-Day Eating Plan to Shed Fat, Boost Testosterone, and Pump Up 
Strength and Stamina.”  As a board-certified internist, one would assume that he 
recognizes hypogonadism as a legitimate disorder on some level, rather than a 
simply “trumped-up disease.”  However, it seems that he would prefer to steer 
readers’ money away from prescription copays and into his own pocket through 
the purchase of his book, a VIP subscription to his personal website, or his e-
commerce store selling various unregulated supplements. 
Men’s Use of Testosterone on the Rise (New York Times, 2013)92  
“The number of middle-aged men with prescriptions for testosterone is 
climbing rapidly… a study published in the journal JAMA Internal Medicine found 
that many men who get prescriptions for the hormone have no evidence of a 
deficiency at all… a quarter of men did not have their levels tested before they 
received the hormone.” 
This NYT Well Blog article primarily examines a 2013 study by Baillargeon 
et al.93 on testosterone prescription trends in the United States between 2001 
and 2011.  Using data from a commercial health insurance database, the study 
found that testosterone use increased from 0.81% in 2001 to 2.91% in 2011 
among men 40 years or older.  For reasons that will be discussed at the end of 
this section, this observed increase is not cause for concern.  Additionally, as this 
cohort included only commercially-insured men over the age of 40 with 
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employment-based plans, its findings cannot be generalized to younger, retired, 
or otherwise unemployed men.   
The Baillargeon study also reported that 25.28% of men who were 
prescribed testosterone therapy did not have a serum testosterone measurement 
recorded in the insurance database.  While this this finding is troubling and 
indefensible, it serves only to highlight the need for more balanced discussion 
and greater education among physicians regarding the diagnosis and treatment 
of hypogonadism.  Indeed, the Endocrine Society9 and European Association of 
Urology recommend confirming the diagnosis of hypogonadism by measuring at 
least two separate serum samples taken in the morning, when testosterone 
levels are highest94.     
Selling That New-Man Feeling (New York Times, 2013)95 
“This marketing juggernaut is running into mounting opposition from some 
prominent medical researchers and industry experts. They contend that the 
pharmaceutical industry has vastly expanded the market for testosterone drugs 
to many men who may not need them and may be exposed to increased health 
risks by taking them. And drug makers have done so, these critics say, by 
exploiting loopholes in federal marketing regulations. Drug makers spent $107 
million last year to advertise the top brand-name testosterone drugs in the United 
States, according to Kantar Media… Drug makers also promote low-T screening 
quizzes directly to consumers, Mr. Mack says, in an effort to prompt men to seek 
testosterone prescriptions from their doctors… The test has also become 
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controversial. Most of the questions invoke symptoms that are so general that 
they could apply to many men who are clinically depressed or simply having a 
bad day — or even to women, says Dr. Adriane J. Fugh-Berman, an associate 
professor at Georgetown University Medical Center in Washington. “There are 
tests that everyone will fail — that is the idea,” says Dr. Fugh-Berman” 
This account, written by Natasha Singer, echoes concerns raised in 
several of the aforementioned write-ups.  While it is true that testosterone sales 
have increased in the past years, this growth is not unprecedented.  From 2012 
to 2013, the amount of testosterone sold in the United States increased by only 
0.6%96.  Indeed, the observed increases and absolute spending on testosterone 
remain modest when compared to other drugs (see figure 4)96,97.  During the 
same time period, there was 1.6% more prescriptions of all types filled in the 
US97.  In contrast, prescriptions for nervous system disorders increased 5.9% 
and those for contraceptives increased 4.6%97.  Between 1988-1994 and 2007-
2010, the use of antidepressants among adults increased four-fold98.  Moreover, 
testosterone does not appear in Schumock et al.’s analysis of the top 15 drugs 
by expenditures in 201399.  Therefore, the growth in testosterone therapy 
probably reflects a broader trend in prescribing patterns across all medical fields 
rather than targeted advertising, as the author of the NYT piece suggests. 
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Figure 4.  Changes in prescribing rates in the US from 2012 to 2013.  As depicted, the 
increase in testosterone prescriptions is relatively low when compared to medications for nervous 
system disorders and contraceptives.  Additionally, the increase in testosterone prescribing is 
less than the total increase reported for all US prescriptions.  Testosterone data calculated from 
the Mohamoud presentation96.  All other data from Aitken et al.97 
 
Another explanation for the increase is the development of more 
convenient testosterone formulations employing transdermal absorption.  
AndroDerm, a testosterone patch worn on non-scrotal skin, was approved by the 
FDA for treatment of hypogonadism in 1995.  In 2000, the biopharmaceutical 
company Abbott Laborities (now known as AbbVie, Inc.) introduced AndgroGel 
1%.  The quick-drying, odorless, clear gel is applied to the shoulders or abdomen 
once daily.  Although the prevalence of needle phobia is difficult to gauge owing 
to the proclivity of those afflicted to avoid healthcare settings, estimates range 
from 3.5 to 10% of the population100.  The transdermal formulations offer a 
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discreet, easy to use alternative to the traditional injections or pellet insertions for 
those who would otherwise refuse testosterone therapy due to an aversion to 
needles.   
The NYT piece also comments on direct-to-consumer advertising (DTCA) 
of pharmaceuticals.  Although it remains ethically controversial, DTCA is a 
remarkably powerful tool in tackling under-diagnosis and under-treatment of 
myriad medical conditions.  In 2004, the FDA reported the results of a consumer 
survey indicating that 23 million people in the US made a medical appointment 
due to DTCA to address a condition they had never previously discussed101. 
These findings augment a 2003 study by Weissman et al. , which found a quarter 
of patients who saw their doctor after seeing DTCA received a new diagnosis, 
nearly half of which were categorized as a “high-priority” health concern102.  
DTCA has also been shown to encourage patient compliance103, improve the 
patient-physician relationship104, mitigate the stigma associated with certain 
diseases105, and make patients more active participants in their healthcare106.  
The author’s supposition that DTCA has increased inappropriate testosterone 
prescribing is very likely false.  Whether or not it is true, the assertion that anyone 
can fail the online quizzes discussed is irrelevant.  The quizzes are not a 
diagnostic tool and the results should be given no bearing by physicians without 
bloodwork to confirm the diagnosis.  Indeed, survey results demonstrate that as 
low as 2% of patients who saw DTCA asked for and were prescribed the 
promoted drug107.  Additionally, research shows that 77% of consumers who 
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discuss the content of DTCA with their doctors are counseled on health and 
lifestyle changes107.  As low testosterone is not screened for, it is arduous to 
estimate the exact number of men with hypogonadism. A 1996 FDA survey 
placed the number at 4-5 million, 95% of whom were not being treated108. A 2006 
study approximated 13.8 million, >90% of whom were not receiving treatment109.  
As of 2013, the percentage of untreated men has dropped significantly, but 50-
85% of hypogonadal men remain untreated96.  The successful DTCA campaign 
for low testosterone is not a nefarious manipulation by the pharmaceutical 
industry; rather, it has likely played an essential role in getting more hypogonadal 
men medical treatment for their medical condition.   
Singer goes on to imply that the manufacturers of testosterone 
formulations spend an exorbitant amount on advertising.  She states that $107 
million was spent in 2012 to advertise the top brands of testosterone-containing 
products, which ostensibly seems very high.  Although the dollar amount does 
not include unbranded low testosterone awareness campaigns, it represents just 
0.4% of the $27.4 billion in total the pharmaceutical industry spent on advertising 
in 2012110.  By contrast, Eli Lilly spent $237 million in 2012 on direct to consumer 
advertising alone for its anti-depression medication, Cymbalta111.  DTCA 
accounted for only 39% of Cymbalta’s total advertising budget for 2012112, which 
means Lilly spent a total of $610 million across all advertising channels for the 
drug.  To reiterate, a single pharmaceutical company spent nearly six times more 
money advertising a single anti-depressant than all manufacturers of brand-name 
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testosterone spent to advertise their various formulations.  In fact, the spending 
on advertising for testosterone pales in comparison to many other drugs (see 
figure 5)112,113.  Testosterone did not appear in the top ten advertised drugs 
ranked by pharmaceutical industry spending in the first quarter of 2012114.   
Figure 5.  Advertising spending for brand-name pharmaceuticals in 2012.  Singer poses the 
$107 million spent on advertising by the manufacturers of brand-name testosterone as egregious, 
but the manufacturers of Cymbalta, Celebrex, Pradaxa, Advair, and Cialis each spent nearly 4-6 
times that amount.  Data for Testosterone is from the Singer NYT piece95.  Data for all other 
drugs calculated from the Cegedim report112 and MM&M report113.   
 
Testosterone prescription rates have increased in recent years in parallel 
with, and likely as a result of, the wealth of evidence supporting its efficacy and 
safety in the treatment of hypogonadal men.  Patients are learning that they need 
not accept low libido, erectile dysfunction, fatigue, and other symptoms severely 
impacting their quality of life as a normal part of the aging process.  Primary care 
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physicians are learning to include hypogonadism in the differential diagnosis for 
these symptoms, order the appropriate tests, and refer to suitable specialists.  
Academicians are learning that testosterone therapy may have a surfeit of 
beneficial effects for hypogonadal men, including kidney health36, 
cardioprotective properties71, and cognitive improvement115.  The prescriptions 
patterns of testosterone-containing product are not the consequence of a 
misleading advertising campaign by the pharmaceutical industry; rather, they are 
the culmination of 150 years of research, and represent a change in the 
landscape of healthcare allowing millions of men live a happier, healthier life.  
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IMPLICATIONS OF THE MEDIA COVERAGE 
The publicity garnered by the four publications linking testosterone therapy 
to cardiovascular risk has had far-reaching implications.   
In June 2014, the US Judicial Panel on Multidistrict Legislation established 
coordinated proceedings in the federal court circuit to consolidate all class action 
lawsuits brought against the manufacturers of testosterone formulations before 
one judge, the Honorable Matthew F. Kennelly.  As of December 23, 2014, there 
were over 700 total actions pending116.  Ambulance-chasing lawyers have started 
buying television and radio advertisements in an attempt to recruit even more 
potential clients.   
Recently a member of the mainstream media attempted to tarnish the 
reputations of several clinicians and researchers for no other reason than their 
advocacy of balanced discussion regarding testosterone therapy.  In a potentially 
libelous Wall Street Journal piece117, Ed Silverman accused the Androgen Study 
Group of attempting to manipulate the results of a NEJM poll118.  The poll 
comprised a vignette describing a 61 year old male presenting with at least three 
clinical symptoms of hypogonadism and two early-morning serum testosterone 
measurements to confirm the diagnosis, presented two opposing expert opinions, 
then asked readers to vote whether or not they would recommend testosterone 
therapy.  The members of ASG sent an email to a limited number of their 
colleagues encouraging them to read and participate in the poll.  When 
Silverman became aware of the email, he misreported the details and highlighted 
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the fact that some members of ASG have received food, beverages, and 
speaking fees from manufacturers of testosterone products.  This manner of 
compensation is innocuous and commonplace; indeed, pharmaceutical 
companies need input from physicians in order to address the needs of patients, 
and physicians should be compensated for their time.  However, Silverman’s 
article implied the actions of the ASG were nefarious and unprecedented.   
The threat of a malpractice lawsuit or attacked by the media is enough to 
make most clinicians rethink their practices.  Many physicians who have caught 
wind of the ongoing testosterone liability litigation may be reluctant to treat 
hypogonadal men; that is, an approved medical treatment is probably being 
withheld from patients with a legitimate medical condition due to fear mongering 
initiated by the mainstream media and exploited by attorneys.  A 2014 survey 
found that only 9.8% of primary care physicians and cardiologists would refer a 
patient with testosterone deficiency to a urologist119.   
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FACTORS UNDERLYING THE MEDIA BIAS 
Clearly, physicians and researchers who are in favor of the responsible 
use of testosterone therapy for the treatment of hypogonadism are being 
lambasted by the media for simply basing their practice on the best evidence 
available.  But why does this discrepancy exist?  As discussed, testosterone has 
been used medically for nearly a century.  What kindling did journalists see in the 
realm of testosterone therapy that they could use to light the fire of hysteria, and 
why did they choose now to launch the attack?   
Controversy 
Controversy, in the dichotomous sense, can be defined as a single set of 
evidence interpreted two different ways to yield two opposing conclusions.  
Clearly, the media thrives on controversy:  Should the United States be at war?  
Should this candidate be elected?  Should this person be found guilty of an 
alleged crime?  People are emotionally invested in these topics, and without 
appealing to that connection through stories of this type, newspapers would lose 
a large portion of their readership.   
Testosterone therapy differs from these examples in that there is little 
controversy surrounding it within the medical community; the overwhelming 
majority of clinicians and researchers familiar with the literature have rejected the 
conclusions of the four studies purporting a connection between testosterone 
therapy in hypogonadal men and cardiovascular risk46–49.  In this case, the media 
did not just write about a controversy: they created one.      
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Abuse of Anabolic Androgenic Steroids 
Of concern to medical professionals is the potential for misuse of 
exogenous androgens for the purposes of sports performance enhancement, a 
practice especially prevalent in many bodybuilding and powerlifting circles.  
There is undoubtedly a dose-dependent relationship in men between 
testosterone levels and the ability to gain lean muscle mass120.  However, little 
evidence exists to support the safety of exogenous testosterone administration in 
eugonadal (T > 300 ng/ml) men or supra-physiological dosing in any gonadal 
state.  Moreover, there are many published case studies involving irresponsible 
anabolic steroid use associated with disease state, including toxic hepatitis121, 
bile acid nephropathy122, cardiomyopathy, and ischemic stroke123.  Accordingly, 
the European Association of Urology10 and the Endocrine Society9, both explicitly 
state testosterone replacement is contraindicated in eugonadal men and 
recommend frequent blood tests for hypogonadal patients receiving testosterone 
therapy. 
Unfortunately, laypeople may subconsciously associate testosterone 
replacement therapy administered by a licensed physician with the stories of 
professional athletes who have been busted for using performance enhancing 
drugs in order to run faster, jump higher, and hit harder.  The latter has drawn an 
astronomical amount of attention in the media, especially over the past decade.  
Journalists are piggybacking off of the success of these stories by irresponsibly 
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and inappropriately blurring the lines between a legitimate medical treatment and 
performance enhancing drug abuse.   
Many in the general public hold a preconceived opinion of testosterone 
tarnished by the portrayal of violent, muscle-bound men with “roid-rage” in 
popular culture.  For many years, the media has been catering to and 
perpetuating this prejudice.  Of particular note is Chris Benoit, a well-known 
World Wrestling Entertainment athlete and abuser of anabolic-androgenic 
steroids who committed suicide in 2007 after murdering his wife and seven-year-
old son.  A slurry of media accounts proposed steroid as an explanation for his 
actions124,125, prompting a federal investigation into performance enhancing drug 
use in professional wrestling. 
Sex 
Sex sells.  It is not just an age-old adage, it is a verifiable scientific 
phenomena: provocative advertisements elicit physiological and cognitive 
reactions126.  The urge for reproduction is what has driven our evolution from 
single-celled organisms to sentient, powerful human beings.  We, as a species, 
have a deeply rooted predisposition to respond to sexual imagery.   
Testosterone is unequivocally associated to sex, and the media jumps at 
every opportunity to exploit the relationship.  Two of the symptoms that most 
profoundly impact quality of life for hypogonadal males are erectile dysfunction 
and loss of libido.   
 41 
The ability of a male to achieve an erection is contingent on 
parasympathetic innervation originating from S2-4 and the target vasculature.  
When aroused by tactile, auditory, or visual stimuli, the brain responds by 
activating the parasympathetic nervous system, which in turn excites the post-
ganglionic cavernosal nerve.  Downstream signaling leads to relaxation of the 
cavernosal smooth muscle and opening of the vascular space, thereby 
increasing arterial blood flow to the penis while venous outflow remains constant.  
As the corpora cavernosa fills with blood, the erectile tissues apply pressure 
against the tunica albuginae, occluding emissary veins and increasing penile 
rigidity.   
As reviewed by Traish and Galoosian127, there is evidence that 
testosterone plays an important role in several aspects of erectile physiology, 
including the function of trabecular smooth muscle, cavernosal and dorsal 
nerves, and vascular endothelium.  Given the profound involvement of 
androgens in the erectile pathway, it is not surprising that the medical literature is 
teeming with studies correlating male sexual dysfunction with hypogonadism.  In 
a cohort of 3,369 European men, erectile dysfunction was shown to be 
significantly related to decreased testosterone levels23.  Accordingly, testosterone 
therapy has been shown to improve sexual function in hypogonadal men 128–132.    
The physiology of sexual desire, though less well understood than that of 
erections, is also highly dependent on testosterone.  Several studies have 
identified the neurotransmitter dopamine as the key player in libido133.  
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Androgens are known to activate nitric oxide pathways that facilitate dopamine 
release, thereby positively modulating sexual desire.  Moreover, testosterone 
therapy has been shown to be extremely effective in increasing sexual desire in 
men134. 
Journalists know all too well that a sensational, hysteria-inducing headline 
will get people reading and a strong sexual component will keep them reading.  
Given the inextricable connection between androgens and all facets of male 
sexuality, it is no surprise that testosterone therapy has become such a hot topic 
in the mainstream media.    
Hypermasculinity 
The general public has an appetite for macabre.  Evidence of this 
phenomenon abounds, from the box office earnings of violent action movies to 
the popularity of television shows glorifying serial killers and other types of 
deranged criminals.  Aggression is interesting, and a common misconception 
exists that it is caused by testosterone.  This inaccurate association is likely 
rooted in the belief that men are more aggressive than women [cite-Archer], and 
men also have higher levels of testosterone coursing through their bodies. “Roid-
rage” has penetrated our society’s vernacular as a way to describe angry 
outbursts in men abusing anabolic-androgenic steroids, but the term’s 
recognition does not reflect its integrity when subjected to repeated scientific 
scrutiny.  A recent well-designed study confirmed that administration of the same 
600mg/wk dose of testosterone to men age 19-40 without preexisting 
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psychopathology did not increase aggressive behavior135.    Additionally, in 2000 
a Harvard group found that just 16% of men receiving 600mg of testosterone per 
week, a markedly supraphysiological dose, experienced some degree of 
hypomania 136.  While 16% is a significant portion of the sample population, it is 
important to distinguish the abuse of supraphysiological levels of anabolic 
steroids from testosterone therapy, a legitimate medical treatment for a medical 
disorder.   
Recently, a Japanese group examined the effects of testosterone therapy 
in adult male patients with Prader-Willi syndrome (PWS), a rare genetic disorder 
known to cause hypogonadism, delayed and incomplete sexual development, 
short stature, behavioral issues, cognitive defects, obesity, and low muscle 
tone137.  The researchers observed tremendously beneficial outcomes, reporting 
a significant increase in secondary sex characteristics, bone density, and muscle 
mass, along with a decrease in body fat.  Importantly, aggression, as measured 
on the Modified Overt Aggression Scale (MOAS) actually decreased during 
testosterone therapy, though the change was not significant (see figure 4). 
Moreover, there is evidence that low testosterone levels can contribute to mild 
depressive disorders, such as dysthymia138. 
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Figure 6. Changes in aggression in Prader-Willi Syndrome patients 
receiving testosterone therapy [Taken from Kido et al137].  The graph 
shows that agression, measured on the MOAS scale, decreased in PWS 
patients after the initiation of testosterone treatment. 
 
 
As demonstrated, there is an abundance of evidence that therapeutic 
levels of testosterone do not cause an increase in aggression, and a lack of 
consistent evidence that abuse of supraphysiological androgen levels cause 
aggressive behavior.  Despite the convincing science, mainstream media 
journalists continue to associate testosterone therapy with steroid abuse and 
imply that both cause an increase in aggressive behavior.  In a 2014 article titled 
“In Men’s Fight Against Aging, How Much Risk to Take?” published in The Wall 
Street Journal, the author states, “Safety concerns have dogged testosterone 
products for decades. Large doses, which some bodybuilders take to bulk up, 
have been linked to aggression.”139  Insulin, a drug used to treat diabetes 
mellitus, has a great deal in common with testosterone:  they both are hormones 
produced naturally by the human body, synthetically synthesized to treat their 
respective deficiency disorders, and abused by bodybuilders and athletes in 
order to build muscle mass140.  Insulin misuse has the potential to be extremely 
lethal, yet the media seldom mentions it, and certainly does not cite is as an 
argument against its application as a therapy for patients with diabetes mellitus.  
To report that testosterone therapy is dangerous because a small subset of 
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people who abuse the substance become more aggressive is ignorant and 
unethical.   
Anti-pharma 
Many Americans harbor distrust for large corporations; indeed, politicians 
and journalists alike have made careers out of demonizing big business.  This 
wariness has carried over to the lay public’s view of large pharmaceutical 
companies (Big Pharma), and with good reason:  the industry’s history is 
burdened with fraud, data suppression, and questionable ethics141.  Journalist 
willing to take on Big Pharma and ‘stick it to the man’ are extolled as white 
knights.  Readers feel empowered when they believe someone is standing up for 
them, and the media harnesses this sense of solidarity to increase circulation. 
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CONCLUSION 
Although it cannot be said with certainty until large, prospective, 
randomized controlled studies are conducted, the overwhelming majority of the 
evidence currently suggests that testosterone therapy is not associated with 
adverse cardiovascular outcomes43-45.  If any correlation does exist, it is likely 
one that offers cardiovascular benefits to hypogonadal patients.  At the present 
time, there is sufficient evidence for practitioners to recognize hypogonadism as 
a risk factor for mortality, atherosclerosis, and obesity30-40.   
Interested parties eagerly await the results of the Testosterone Trials142, a 
coordinated set of seven clinical trials intended to definitively discern whether or 
not testosterone therapy in hypogonadal elderly men is efficacious in improving 
mobility, sexual function, fatigue, cognitive function, hemoglobin, bone density, 
and coronary artery plaque volume.  Although this study is not primarily designed 
to examine the relationship between testosterone therapy and cardiovascular 
risk, it should provide valuable data to steer the conversation and future 
research.   
The mainstream media has chosen to ignore the science suggesting 
testosterone therapy is safe and efficacious, and instead bring four flawed 
studies linking testosterone to cardiovascular risk into the public spotlight with 
sensationalist headlines and imbalanced reporting.  This coverage has had a 
significant impact on the lay public’s perception of testosterone therapy, and has 
even penetrated as far as to alter the discourse within the medical community.  
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Indeed, a geriatrician recently indicated that anyone who recognizes age-related 
hypogonadism as a legitimate and treatable medical condition is guilty of 
“disease mongering”143. 
The media plays an important role in healthcare, often serving as a 
valuable source of information for patients.  This creates a level of transparency 
in the healthcare industry and holds pharmaceutical companies, researchers, 
and clinicians accountable for unethical practices.  However, a very important 
line has been crossed in the media’s coverage of testosterone therapy in men: 
physicians, influenced by media-driven hysteria and fear, are withholding 
testosterone treatment from patients who suffer from hypogonadism.  These 
abandoned patients are forced to either live without treatment for their medical 
condition, or turn to “anti-aging” walk-in testosterone clinics for a lower and 
dangerous standard of care.  As Dr. Morgentaler so eloquently wrote in 2014, 
“The current outrage over the use of T therapy, anchored by the flimsiest of 
evidence regarding CV risk, should be regarded as hormonophobia. However, 
the true outrage is that men whose health and quality of life have been impacted 
by a highly prevalent hormone deficiency may fail to receive treatment due to 
social forces and hysteria that are unrelated to medical science.”144 It is 
absolutely unethical for the media to interfere in the patient-physician relationship 
when the best evidence clinicians have available points to testosterone being a 
safe and efficacious treatment for the majority of hypogonadal men.  When it 
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comes to healthcare, journalists should be bound by the same principles of 
bioethics that physicians are taught to adhere to:  first, do no harm.   
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